Science

Emre Yekedüz: New findings in high-risk NMIBC after BCG failure

Emre Yekedüz/X

Jan 20, 2025, 13:55

Emre Yekedüz: New findings in high-risk NMIBC after BCG failure

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, posted on X about recent paper by Charalampos Fragkoulis et al., titled “Intravesical Administration of Durvalumab for High-risk Non–muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group” published on Science Direct.

Authors: Charalampos Fragkoulis, Aristotelis Bamias, Nikos Gavalas, Kimon Tzannis, Evangelos Fragiadis, Alexandros Pinitas, Panayiotis V. Stamatakos, George Papadopoulos, George Stathouros, Xanthippi Grammatoglou, Penelope Korkolopoulou, Christina Zoubouli, Konstantinos Stravodimos, Konstantinos Ntoumas, Dionysios Mitropoulos, Andreas Skolarikos, Athanasios Papatsoris

“New findings in high-risk NMIBC after BCG failure.

Single-arm phase 2 trial tested intravesical durvalumab (1000 mg every 6 weeks) in 30 patients.

1-yr high-grade relapse-free rate: 39%
Bladder-intact survival at 1 yr: 78%
Minimal toxicity: Grade 1 haematuria in 17% of patients.”

Alexandros Pinitas Andreas Skolarikos Aristotelis Bamias Athanasios Papatsoris cancer Charalampos Fragkoulis Christina Zoubouli Dionysios Mitropoulos Emre Yekedüz Evangelos Fragiadis George Papadopoulos George Stathouros Kimon Tzannis Konstantinos Ntoumas Konstantinos Stravodimos Nikos Gavalas NMIBC OncoDaily Oncology Panayiotis V. Stamatakos Penelope Korkolopoulou Science Direct Xanthippi Grammatoglou

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success